TY - JOUR
T1 - Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction
T2 - J-TASTE Trial
AU - on behalf of J-TASTE investigators
AU - Takahama, Hiroyuki
AU - Asakura, Masanori
AU - Abe, Yukio
AU - Ajioka, Masayoshi
AU - Aonuma, Kazutaka
AU - Anzai, Toshihisa
AU - Hayashi, Takaharu
AU - Hiramitsu, Shinya
AU - Kawai, Hiroya
AU - Kioka, Hidetaka
AU - Kimura, Kazuo
AU - Lim, Young Jae
AU - Matsuoka, Ken
AU - Motoki, Hirohiko
AU - Nagata, Yoji
AU - Nakamura, Sunao
AU - Ohte, Nobuyuki
AU - Ozaki, Yukio
AU - Sasaoka, Taishi
AU - Tamaki, Shunsuke
AU - Hamasaki, Toshimitsu
AU - Kitakaze, Masafumi
N1 - Funding Information:
Conflict of Interest H.T. reports grants from The Bayer Scholarship for Cardiovascular Research; grants from Japan Ministry of Education, Culture, Sports, Science and Technology; personal fees from Otsuka; personal fees from Ono Pharmaceutical Co.; and personal fees from Daiichi Sankyo. M. K. reports grants and personal fees from Takeda, during the conduct of the study, and grants from Japanese government; grants from Japan Heart Foundation; grants from Japan Cardiovascular Research Foundation; grants and personal fees from Asteras; grants and personal fees from Sanofi; personal fees from Daiichi Sankyo; grants and personal fees from Pfizer; grants and personal fees from Ono; personal fees from Bayer; grants and personal fees from Novartis; personal fees from Behringer; grants and personal fees from Tanabe Mitsubishi; personal fees from Kowa; grants and personal fees from Kyowa Hakko Kirin; personal fees from Dainippon Sumitomo; personal fees from Sawai; personal fees from MSD; grants and personal fees from Abbott; grants and personal fees from Otsuka; grants from Calpis; grants from Nihon Kohden; personal fees from Shionogi; personal fees from AstraZeneca; personal fees from Asahi Kasei Med.; personal fees from Novo Nordisk; personal fees from Fujifilm RI; and personal fees from Japan Medical Data. Dr. Asakura reports grants from Actelion Pharmaceutical Japan; grants from Boehringer Ingelheim Japan, Inc.; personal fees from Otsuka Pharmaceutical Co., Ltd.; personal fees from Sanofi K.K.; personal fees from Bayer Yakuhin, Ltd.; personal fees from MSD K.K.; personal fees from Takeda Pharmaceutical Company Limited; personal fees from Ono Pharmaceutical Co., LTD.; personal fees from Mitsubishi Tanabe Pharma Corporation; personal fees from Daiichi Sankyo; personal fees from Pfizer Japan Inc.; and personal fees from Astellas Amgen Biopharma, outside the submitted work. Dr. Abe reports grants from Teijin, grants from Abbott, grants from Shionogi, grants and personal fees from Daiichi Sankyo, grants and personal fees from Bayer, grants and personal fees from Bristol-Myers Squibb, grants from Ono, grants from Novartis, grants from Pfizer, personal fees from Toa Eiyo, personal fees from Boehringer Ingelheim, personal fees from Dainippon Sumitomo, personal fees from Otsuka, personal fees from Philips, personal fees from GE, personal fees from Siemens, and grants from Japanese government, outside the submitted work. Dr. Ajioka has nothing to disclose. Dr. Aonuma has nothing to disclose. Dr. Anzai has nothing to disclose. Dr. Hayashi has nothing to disclose. Dr. Hiramitsu reports personal fees from null, during the conduct of the study, and personal fees from Tanabe Mitsubishi; personal fees from Daiichi Sankyo; personal fees from Bayer; personal fees from Takeda; personal fees from Asteras; personal fees from MSD; and personal fees from Kowa, from null, outside the submitted work. Dr. Kawai has nothing to disclose. Dr. Kioka has nothing to disclose. Dr. Kimura has nothing to disclose. Dr. Lim has nothing to disclose. Dr. Matsuoka has nothing to disclose. Dr. Motoki has nothing to disclose. Dr. Nagata has nothing to disclose. Dr. Nakamura has nothing to disclose. Dr. Ohte has nothing to disclose. Dr. Ozaki has nothing to disclose. Dr. Sasaoka has nothing to disclose. Dr. Tamaki reports non-financial support from Bristol-Myers Squibb Company, non-financial support from Eli Lilly and Company, nonfinancial support from Otsuka Pharmaceutical, non-financial support from Boehringer Ingelheim, non-financial support from Toa Eiyo, nonfinancial support from Nihon Medi-Physics, non-financial support from Medtronic, and non-financial support from Nikkei Business Publications, outside the submitted work. Dr. Hamasaki has nothing to disclose. Dr. Kitakaze reports grants from Japanese government, during the conduct of the study, and grants from Japanese government; grants from Japan Heart Foundation; grants from Japan Cardiovascular Research Foundation; grants and personal fees from Asteras; personal fees from Daiichi Sankyo; grants and personal fees from Pfizer; grants and personal fees from Ono; personal fees from Bayer; grants from Novartis; grants and personal fees from Tanabe Mitsubishi; personal fees from Kowa; personal fees from MSD; grants from Nihon Kohden; personal fees from Shionogi; personal fees from Astrazeneca; grants and personal fees from Astra Zeneca; personal fees from Taisho Toyama; personal fees from Toyama Kagaku; grants and personal fees from Kureha; and personal fees from Toa Eiyo, outside the submitted work.
Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Background: Previous studies suggest that the pathophysiology of heart failure with preserved ejection fraction (HFpEF) is characterized not only by high ventricular stiffness, but also by vascular stiffness. Azilsartan has higher vascular affinity compared with other angiotensin II receptor blockers (ARBs), which were proven to have no beneficial effects on clinical outcomes in patients with HFpEF in earlier clinical trials. We aimed to test the hypothesis that azilsartan may improve left ventricular diastolic function in HFpEF patients with hypertension in this trial. Methods: The Effects of Angiotensin Receptor Blockers on Diastolic Function in Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE trial is a multicenter, randomized, open-labeled, and assessor(s)-blinded, active controlled using candesartan, parallel-group clinical trial, to compare changes in left ventricular (LV) diastolic dysfunction between HFpEF patients with hypertension who have received candesartan or azilsartan for 48 weeks. The primary endpoint is the change in early diastolic wave height/early diastolic mitral annulus velocity (E/e’) assessed by echocardiography from the baseline to the end of the study (48 weeks). A total of 190 patients will be recruited into the study. Conclusions: The design of the J-TASTE trial will provide data on whether differences between the effects of the two tested drugs on LV diastolic function exist in HFpEF patients with hypertension and will improve understanding of the pathophysiological role of vascular stiffness on diastolic function.
AB - Background: Previous studies suggest that the pathophysiology of heart failure with preserved ejection fraction (HFpEF) is characterized not only by high ventricular stiffness, but also by vascular stiffness. Azilsartan has higher vascular affinity compared with other angiotensin II receptor blockers (ARBs), which were proven to have no beneficial effects on clinical outcomes in patients with HFpEF in earlier clinical trials. We aimed to test the hypothesis that azilsartan may improve left ventricular diastolic function in HFpEF patients with hypertension in this trial. Methods: The Effects of Angiotensin Receptor Blockers on Diastolic Function in Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE trial is a multicenter, randomized, open-labeled, and assessor(s)-blinded, active controlled using candesartan, parallel-group clinical trial, to compare changes in left ventricular (LV) diastolic dysfunction between HFpEF patients with hypertension who have received candesartan or azilsartan for 48 weeks. The primary endpoint is the change in early diastolic wave height/early diastolic mitral annulus velocity (E/e’) assessed by echocardiography from the baseline to the end of the study (48 weeks). A total of 190 patients will be recruited into the study. Conclusions: The design of the J-TASTE trial will provide data on whether differences between the effects of the two tested drugs on LV diastolic function exist in HFpEF patients with hypertension and will improve understanding of the pathophysiological role of vascular stiffness on diastolic function.
KW - Angiotensin II receptor blocker
KW - Diastolic function
KW - Heart failure with preserved ejection fraction
UR - http://www.scopus.com/inward/record.url?scp=85049582931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049582931&partnerID=8YFLogxK
U2 - 10.1007/s10557-018-6799-5
DO - 10.1007/s10557-018-6799-5
M3 - Article
C2 - 29974299
AN - SCOPUS:85049582931
VL - 32
SP - 381
EP - 388
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
SN - 0920-3206
IS - 4
ER -